Akero Therapeutics, Inc.

NasdaqGS:AKRO Stock Report

Market Cap: US$4.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Akero Therapeutics Management

Management criteria checks 2/4

Akero Therapeutics' CEO is Andrew Cheng, appointed in Sep 2018, has a tenure of 7.25 years. total yearly compensation is $10.47M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $15.23M. The average tenure of the management team and the board of directors is 6.7 years and 6.7 years respectively.

Key information

Andrew Cheng

Chief executive officer

US$10.5m

Total compensation

CEO salary percentage6.55%
CEO tenure7.3yrs
CEO ownership0.3%
Management average tenure6.7yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

Seeking Alpha • Oct 10

Akero: Novartis Acquisition Puts Focus On Unprecedented MASH Data With EFX

Summary Akero Therapeutics is being acquired by Novo Nordisk for up to $5.2 billion, driven by strong phase 2b results for EFX in F2/F3 pre-cirrhotic and compensated cirrhosis F4 MASH patients. Akero's EFX showed unprecedented reversal of cirrhosis and significant fibrosis improvement in the HARMONY and SYMMETRY studies, respectively, positioning it as a leader in FGF21 analogs. The acquisition includes $54 per share upfront as cash and a $6 per share CVR contingent on FDA approval for compensated cirrhosis due to MASH patients by 2031. I maintain a 'Strong Buy' rating on AKRO, citing ongoing phase 3 SYNCHRONY progress and the transformative potential of the Novo Nordisk deal set forth. Read the full article on Seeking Alpha
Seeking Alpha • Apr 06

Akero Therapeutics: Cirrhosis Reversal Data Derisks The Stock

Summary Akero Therapeutics' EFX showed remarkable efficacy in reversing cirrhosis in the long-term SYMMETRY trial, a significant milestone in MASH treatment. EFX demonstrated consistent efficacy across different MASH stages, positioning it uniquely against competitors like Resmetirom, which only targets F2 and F3 MASH. Akero's financial health is strong, with a cash runway until 2028, bolstered by a recent $350 million upsized offering. Despite promising data, potential delays and reliance on surrogate endpoints pose risks; a cautious approach with a pilot position and accumulation at dips is advised. Read the full article on Seeking Alpha
Seeking Alpha • Jan 28

Some Good MASH/NASH News From Akero Therapeutics

Summary One of the best candidates for treatment of MASH recently has been a hormone called FGF21. There are three different FGF21 receptor types, and there have been several analogs of the hormone (with different pharmacokinetic and receptor-binding profiles) entering clinical trials. One of these (exfruxifermin) just produced some extremely interesting clinical results. Akero Therapeutics reported 96-week data in its trial of advanced MASH patients, and there seem really significant signs of improvement compared to placebo. We can expect a number of other trial results from both AKRO and their competitors in the coming months. Read the full article on Seeking Alpha
Seeking Alpha • Dec 31

Akero Therapeutics: Where This Potential MASH Play Stands Currently

Summary Akero Therapeutics, Inc. is a clinical-stage biotech firm that is developing therapies to restore metabolic balance and improve health, with a market cap near $2 billion. The company has made some pipeline progress since we last visited this potential MASH play back in August of last year. Akero's primary and only candidate is moving into Phase 3 development, and the stock has some enthusiastic views on it within the analyst firm community. An updated analysis around AKRO stock follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 20

Akero Therapeutics: Good Candidate For The MASH Basket

Summary Akero Therapeutics' Efruxifermin (EFX) showed strong results in pre-cirrhotic MASH, but failed in cirrhotic MASH, impacting stock performance. The MASH market is highly competitive with many pipeline drugs and one approved drug, resmetirom, creating significant risk for AKRO. Akero has a solid cash runway until 2027, providing financial stability for ongoing trials and potential future data releases. EFX's potential success in early-stage MASH makes AKRO a viable part of a diversified investment in MASH players like MDGL, ETNB, VKTX, IVA and IONS. Read the full article on Seeking Alpha
Seeking Alpha • Apr 03

Akero Therapeutics' EFX Data Warrants Caution

Summary Akero Therapeutics' week 96 Harmony trial data findings and reporting warrant caution due to biomarker data regression and inconsistent findings. In our view, Efruxifermin's phase 2 data reveal a fragile efficacy profile and a concerning safety record, casting doubt on its potential to successfully translate into phase 3 trials. MASH space growing competition and future sales of Resmetirom will significantly impact valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

Summary Akero Therapeutics, Inc. preliminary positive 96-week results from the phase 2b HARMONY study achieved, which used EFX for the treatment of pre-cirrhotic MASH patients with F2-F3 Fibrosis. The global non-alcoholic steatohepatitis market size is expected to reach $14.53 billion by 2028. 96-week results from the phase 2b SYMMETRY study, using EFX for the treatment of patients with compensated cirrhosis (F4) MASH, expected in Q1 of 2024. Akero Therapeutics has $569.3 million in cash as of December 31, 2023; Enough cash to fund its operations into 2026. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Andrew Cheng's remuneration changed compared to Akero Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$293m

Jun 30 2025n/an/a

-US$284m

Mar 31 2025n/an/a

-US$269m

Dec 31 2024US$10mUS$686k

-US$252m

Sep 30 2024n/an/a

-US$237m

Jun 30 2024n/an/a

-US$204m

Mar 31 2024n/an/a

-US$179m

Dec 31 2023US$9mUS$660k

-US$152m

Sep 30 2023n/an/a

-US$120m

Jun 30 2023n/an/a

-US$116m

Mar 31 2023n/an/a

-US$112m

Dec 31 2022US$10mUS$624k

-US$112m

Sep 30 2022n/an/a

-US$121m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021US$4mUS$570k

-US$101m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$95m

Mar 31 2021n/an/a

-US$82m

Dec 31 2020US$5mUS$523k

-US$79m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$59m

Mar 31 2020n/an/a

-US$50m

Dec 31 2019US$5mUS$450k

-US$44m

Sep 30 2019n/an/a

-US$90m

Jun 30 2019n/an/a

-US$86m

Mar 31 2019n/an/a

-US$87m

Dec 31 2018US$1mUS$133k

-US$82m

Compensation vs Market: Andrew's total compensation ($USD10.47M) is above average for companies of similar size in the US market ($USD7.00M).

Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.

CEO

Andrew Cheng (58 yo)

7.3yrs
Tenure
US$10,465,855
Compensation

Dr. Andrew Cheng, MD, PhD, serves as Board Chairman at Expedition Therapeutics Inc. He serves as Director of Vera Therapeutics, Inc. since May 2017. He served as Director of Arbutus Biopharma Corporation s...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Cheng
President7.3yrsUS$10.47m0.34%
$ 15.2m
Jonathan Young
Co-Founder7.3yrsUS$3.04m0.26%
$ 11.6m
William White
Executive VP6.7yrsUS$3.07m0.012%
$ 555.1k
Scott Gangloff
Chief Technical Officer1.7yrsUS$6.22m0.0062%
$ 277.5k
Catriona Yale
Executive VP & Chief Development Officer7.2yrsUS$3.04m0.034%
$ 1.5m
Timothy Rolph
Co-Founder & Chief Scientific Officer8.7yrsUS$3.49m0.29%
$ 13.0m
Thomas Ross
Senior VP & Head of Legalless than a yearno datano data
John Schembri
Senior VP & Head of Finance1.9yrsno datano data
Patrick Lamy
Senior Vice President of Commercial Strategy2.9yrsno data0.0037%
$ 167.1k
6.7yrs
Average Tenure
54yo
Average Age

Experienced Management: AKRO's management team is seasoned and experienced (6.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Cheng
President7.9yrsUS$10.47m0.34%
$ 15.2m
Seth Harrison
Independent Director6.7yrsUS$478.38k0.35%
$ 15.5m
Jane Pritchett Henderson
Independent Director6.7yrsUS$499.63k0%
$ 0
Mark Iwicki
Independent Chairman of the Board7.1yrsUS$519.63k0%
$ 0
Tomas Heyman
Independent Director5.5yrsUS$494.63k0%
$ 0
Graham L. Walmsley
Independent Director7.5yrsUS$492.13k0.11%
$ 5.1m
Yuan Xu
Independent Director4.7yrsUS$487.13k0%
$ 0
Judy Chou
Independent Director4.4yrsUS$484.63k0%
$ 0
6.7yrs
Average Tenure
59yo
Average Age

Experienced Board: AKRO's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/08 00:59
End of Day Share Price 2025/12/08 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Akero Therapeutics, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Alexandria HammondBofA Global Research
Citi ResearchCitigroup Inc